Director/PDMR Shareholding
Dr. Roch Doliveux, a Non-Executive Director and Chair of Oxford Biomedica PLC, has purchased 20,250 ordinary shares at £5.05 per share on the London Stock Exchange, totaling £102,262.50. Following this transaction, Dr. Doliveux now holds 459,055 shares, representing 0.379% of the Company's issued share capital. This purchase by a director is a positive indicator for the company's stock.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK – 24 September 2026: OXB (LSE: OXB) (the “Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Roch Doliveux, a Non-Executive Director and Chair of the Company, has purchased 20,250 ordinary shares of 50p each (“Ordinary Shares”) in the Company on 23 September 2026 on the London Stock Exchange at a price of £5.05. Following this purchase, Dr. Roch Doliveux holds 459,055 shares representing 0.379% of the Company.
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Dr. Roch Doliveux | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 23-September-2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Purchase of shares | ||||
| e) | Place of the transaction | London Stock Exchange (XLON) | ||||
| f) | Currency | GBP – British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 20,250 £5.05 £102,262.50 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.